The quantification of immune gene expressions enables the measurement of the naturally occurring immune activity of the tumor and has been designed to assess particularly the adaptive immunity and the immune suppression in the tumor microenvironment. Within clinical trials, Immunosign® 15 and Immunosign® 21 can provide prognostic and predictive information for cancer immunotherapy development and guide for combination therapy strategy.
Proof-of-concept for prognostic and predictive values of Immunosign® 15/21 have been obtained on retrospective cohorts of colorectal cancer patients and on 9 other cancer types(Galon et al. Immunity 2013, and personal communication, Spicer J.F. et al., 2017, Marabelle A. et al., 2017).
Immunosign® is performed on Nanostring nCounter®. A dedicated bioinformatics pipeline allows to report a comprehensive analysis of data obtained with Immunosign®.